⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

MANKIND - IntraDay Trade Analysis with Live Signals

← Back to List

⭐ Rating: 2.3

Last Updated Time : 19 Sept 26, 11:48 am

Key Parameters

⭐ IntraDay Trade Rating: 2.3

RSI43.2
MACD-41.4
Volume5,65,490
Avg Vol 1Wk5,51,490
Low price1,910 ₹
High price2,674 ₹
Current Price2,301 ₹
DMA 502,381 ₹
Show all parameters (20 more)
Stock CodeMANKIND
Market Cap95,236 Cr.
High / Low2,674 ₹
Stock P/E42.1
Book Value397 ₹
Dividend Yield0.04 %
ROCE13.7 %
ROE13.8 %
Face Value1.00 ₹
DMA 2002,355 ₹
Chg in FII Hold-0.79 %
Chg in DII Hold0.93 %
PAT Qtr558 Cr.
PAT Prev Qtr732 Cr.
PEG Ratio2.07
Debt to equity0.34
52w Index51.2 %
Qtr Profit Var34.5 %
EPS52.8 ₹
Industry PE34.8

🧾 Trade Setup

Aggressive entry recommended. Buy at 2,305 ₹ – this provides a buffer against immediate intraday weakness. Initial exit level should be set at 2,360 ₹ for a 2% profit target, backed by the recent high of 2,674 ₹. A stop-loss order should be placed immediately at 2,280 ₹ to limit downside risk if momentum falters – this is highly sensitive given the overvaluation.

✅ Positive

High volume today (5.65M) suggests significant interest, and the recent DII increase (0.93%) indicates some buying pressure. The Q2 profit surge (558 Cr.) compared to the previous quarter’s 732 Cr., while a decline, is still positive, and the stock has recently traded near its high of 2,674 ₹.

⚠️ Limitation

The extremely elevated P/E ratio of 42.1 versus the industry average of 34.8 suggests significant overvaluation – this leaves little margin for error if sentiment shifts. Furthermore, the negative MACD (-41.4) indicates a weakening momentum and potential downward pressure as the market opens.

📉 Company Negative News

Univest reports suggest Mankind Pharma is facing price drops, indicating a cautious approach from investors despite earnings growth.

📈 Company Positive News

The Q2 profit surge of 558 Cr. exceeded some analyst expectations, contributing to limited selling pressure today.

🏭 Industry

Pharmaceuticals are generally considered defensive but have recently seen significant volatility due to regulatory changes and competition; a strong earnings report can provide a temporary boost, however.

Choose Technical Analysis or Fundamental Analysis above to load it.

How MANKIND Rates Across All Strategies

★ 3.2
Entry Price: 2,280 ₹.
Intraday
★ 2.3
You're viewing this analysis below.
★ 2.6
An ideal entry zone would be between ₹2,100 - ₹2,250, representing a…
★ 2.5
Based on the current data, a conservative entry zone would be between…

NIFTY 50 · Intraday Trading

NEXT 50 · Intraday Trading

MIDCAP · Intraday Trading

SMALLCAP · Intraday Trading